Riboxx GmbH

Riboxx GmbH is a German biopharmaceutical company that develops, manufactures and markets drugs for the immunotherapy of cancer and virus diseases. Its therapeutic approach is based on switching the immune system on by activating the innate immune system. The company's drug products belong to the class of Toll-like-Receptor 3 (TLR3) agonists and RIG-I-like-Receptor (RLR) agonists, and the active drug substance is RNA (ribonucleic acid). Riboxx has developed four families of TLR3 and RLR agonists for immunotherapy. For cancer immunotherapy, RIBOXXIM is a TLR3 ligand for ex vivo immunotherapy of cancer, therapeutic vaccination against cancer, and prevention of cancer recurrence; APOXXIM is a TLR3 ligand for first-line immunotherapy of cancer; and RIBOXXON is a TLR3-bioconjugate for targeted immunotherapy of cancer. For immunotherapy of virus diseases, RIBOXXOL is a TLR3 ligand for therapeutic vaccination against virus diseases such as Hepatitis B virus. Beyond its own drug development, Riboxx supplies its GMP TLR3 ligands to pharmaceutical companies and public institutions conducting Phase I to III clinical trials. These ligands are manufactured in three standard scales — 1 gram per batch, 5 grams per batch, or 10 grams per batch — with higher scales feasible on demand. The company presents itself under the Riboxx Pharmaceuticals name and operates a dedicated pharmaceutical website alongside its main corporate site. Riboxx is headquartered in Dresden, Germany, reflected in its +49 (0)351 telephone prefix. It is a privately held company. Its business model combines proprietary immunotherapy drug development with the supply of research-grade and GMP-grade immune-activating RNA ligands to external clinical programs.

Riboxx GmbH is a German biopharmaceutical company focused on RNA-based immunotherapy. It develops, manufactures and markets drugs intended for the immunotherapy of cancer and virus diseases. The company's scientific foundation rests on activating the innate immune system: its drug products act by switching the immune system on, and they belong to the class of Toll-like-Receptor 3 (TLR3) agonists and RIG-I-like-Receptor (RLR) agonists, with RNA (ribonucleic acid) as the drug substance. From this platform, Riboxx has developed four families of TLR3 and RLR agonists. For cancer immunotherapy, the company created RIBOXXIM, a TLR3 ligand for ex vivo immunotherapy of cancer, therapeutic vaccination against cancer, and prevention of cancer recurrence; APOXXIM, a TLR3 ligand for first-line immunotherapy of cancer; and RIBOXXON, a TLR3-bioconjugate for targeted immunotherapy of cancer. For immunotherapy of virus diseases, it developed RIBOXXOL, a TLR3 ligand for therapeutic vaccination against virus diseases such as Hepatitis B virus. In addition to its own therapeutic programs, Riboxx built a supply business around its GMP TLR3 ligands. These ligands — RIBOXXIM, APOXXIM, RIBOXXON and RIBOXXOL — are made available to pharmaceutical companies and public institutions performing Phase I to III clinical trials. The company manufactures them in three standard scales: 1 gram per batch, 5 grams per batch, or 10 grams per batch, with higher scales feasible on demand. This dual model positions Riboxx both as a drug developer and as a supplier of immune-activating RNA ligands to the broader clinical research community. The company is headquartered in Dresden, Germany, as indicated by its +49 (0)351 telephone number, and it presents its pharmaceutical activities under the Riboxx Pharmaceuticals name. It is a privately held enterprise. Detailed public information about its founding date, founders, ownership structure and executive leadership is limited in the available sources.

Developer and supplier of RNA-based innate immune activators (TLR3 and RLR agonists) for cancer and viral-disease immunotherapy, serving both proprietary drug programs and external clinical-stage partners.

• RIBOXXIM

  TLR3 ligand for ex vivo immunotherapy of cancer, therapeutic vaccination against cancer, and prevention of cancer recurrence.

• APOXXIM

  TLR3 ligand for first-line immunotherapy of cancer.

• RIBOXXON

  TLR3-bioconjugate for targeted immunotherapy of cancer.

• RIBOXXOL

  TLR3 ligand for therapeutic vaccination against virus diseases, i.e. Hepatitis B virus.

1. 1home - RIBOXX Pharmaceuticalsriboxx-pharma.com
2. 2Riboxx GmbH - Wikidatawikidata.org